The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM ‐specific immunotherapy
Clinical & Experimental Allergy · 2023
DOI: 10.1111/cea.14293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2023. Verfasst von Eduardo Santos da Silva und 19 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Allergology and Acarology (LAA), Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil. Hauptthemen laut MEDLINE: Hypersensitivity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado da Bahia.
Abstract (Originalsprache)
Background
Allergen‐specific immunotherapy (AIT) is the only disease‐modifying treatment approach to change disease‐causing allergens. Hypoallergenic derivatives show promise as potential therapeutics, amongst which BTH2 was designed to induce tolerance against Blomia tropicalis allergy. Our aim was to investigate the hypoallergenicity and immunoregulatory activity of BTH2 in vitro and its therapeutic potential in a mouse model of AIT.
Methods
Recombinant Blo t 5 and Blo t 21 allergens and their hybrid derivatives (BTH1 and BTH2) were expressed and purified. IgE binding capacity was tested by ELISA using sera from Brazilian, Colombian, and Ecuadorian subjects. Secretion of cytokines in supernatants from human cell cultures was measured following stimulation with the four recombinants and controls. The capacity of BTH2 to ameliorate allergic airway inflammation induced by B. tropicalis extract was evaluated in a murine model of AIT. Results rBlo t 5 and rBlo t 21 were identified as major allergens in Latin American patients, and BTH2 had the lowest IgE binding. In vitro stimulation of human cells induced greater levels of IL‐10 and IFN‐γ and reduced the secretion of Th2 cytokines. BTH2 ameliorated allergic airway inflammation in B. tropicalis ‐challenged A/J mice, as evidenced by the histopathological and humoral biomarkers: decreased Th2 cytokines and cellular infiltration (especially eosinophils), lower activity of eosinophil peroxidase, an increase in IgG blocking antibodies and strong reduction of mucus production by goblet cells.
Conclusions
Our study shows that BTH2 represents a promising candidate for the treatment of B. tropicalis allergy with hypoallergenic, immune regulatory and therapeutic properties. Further pre‐clinical studies are required in murine models of chronic asthma to further address the efficacy and safety of BTH2 as a vaccine against B. tropicalis ‐induced allergy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Allergology and Acarology (LAA), Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil.
- Post-Graduate Program in Biotechnology of the Northeast Biotechnology Network (RENORBIO), Maceió, Brazil.
- Post-Graduate Program in Immunology, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil.
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FioCruz), Salvador, Brazil.
- Faculty of Health Sciences, Technical University of Ambato, Ambato, Ecuador.
- Department of Pharmacy, University of Cartagena, Cartagena, Colombia.
ORCID-Profile: Eduardo Santos da Silva, Marina Borges Rabelo de Santana, Elisânia Fontes Silveira, Raphael Chagas Silva, Antônio Márcio Santana Fernandes, Emília Maria Medeiros de Andrade Belitardo, Luis Fabián Salazar Garcés, Leonardo Freire Santiago, Josefina Zakzuk, Luis Gustavo Carvalho Pacheco, Fatima Ferreira, Philip Cooper, Carina da Silva Pinheiro, Neuza Maria Alcantara-Neves
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado da Bahia
Zitieren
APA
da Silva, E. S., de Santana, M. B. R., Silveira, E. F., Torres, R. T., Silva, R. C., Fernandes, A. M. S., Belitardo, E. M. M. A., Garcés, L. F. S., Santiago, L. F., Urrego, J. R., Vilas-Bôas, D. S., de Freitas, L. A. R., Zakzuk, J., Pacheco, L. G. C., Cruz, Á. A., Ferreira, F., Cooper, P., Caraballo, L., Pinheiro, C. D. S., & Alcantara-Neves, N. M. (2023). The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM ‐specific immunotherapy. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14293
Vancouver
da Silva ES, de Santana MBR, Silveira EF, Torres RT, Silva RC, Fernandes AMS, et al. The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM ‐specific immunotherapy. Clinical & Experimental Allergy. 2023. doi:10.1111/cea.14293
BibTeX
@article{daSilva2023,
author = {da Silva, Eduardo Santos and de Santana, Marina Borges Rabelo and Silveira, Elisânia Fontes and Torres, Rogério Tanan and Silva, Raphael Chagas and Fernandes, Antônio Márcio Santana and Belitardo, Emília Maria Medeiros de Andrade and Garcés, Luis Fabián Salazar and Santiago, Leonardo Freire and Urrego, Juan Ricardo and Vilas-Bôas, Deise Souza and de Freitas, Luiz Antônio Rodrigues and Zakzuk, Josefina and Pacheco, Luis Gustavo Carvalho and Cruz, Álvaro Augusto and Ferreira, Fatima and Cooper, Philip and Caraballo, Luis and Pinheiro, Carina da Silva and Alcantara-Neves, Neuza Maria},
title = {The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM ‐specific immunotherapy},
journal = {Clinical & Experimental Allergy},
year = {2023},
doi = {10.1111/cea.14293}
}
EUVIMED